Program
JNJ-64264681
Its studies are mostly in Lymphoma, Non-Hodgkin · Leukemia, Myeloid, Acute, led by Johnson & Johnson.
Furthest: phase 1, since Jul 24, 20184 company-led studies, 1 open or runningNext primary completion: Jan 19, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 41 open or running | phase 1since Jul 24, 2018 | Jul 24, 2018 | Jan 19, 2028phase 1 · NCT06788509 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 24, 2018First study: phase 1 study in HealthyFirst studyNCT03607513 · 105 enrolled · Belgium
- Dec 23, 2019Phase 1 study in Lymphoma, Non-HodgkinNCT04210219 · 85 enrolled · United States, Georgia, Moldova and more
- Dec 1, 2020Phase 1 study in Lymphoma, Non-HodgkinNCT04657224 · 75 enrolled · United States, Australia, Belgium and more
- Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more
Ahead
- Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509
TargetBeta
BTK →read by rule
“An orally bioavailable and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK), ”NCIt, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more | 1 | By invitation | Jan 19, 2028 | 120 |
| NCT04657224Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 1 | Completed | Jan 16, 2025 | 75 |
| NCT04210219Lymphoma, Non-Hodgkin · United States, Georgia, Moldova and more | 1 | Completed | May 28, 2025 | 85 |
| NCT03607513Healthy · Belgium | 1 | Completed | Aug 9, 2019 | 105 |
How it is read
Names in the registry
- “JNJ-64264681”, 4 entries
Conditions, from the studies’ own filings
- Lymphoma, Non-Hodgkin, 2 studies
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.